scholarly article | Q13442814 |
P5530 | Altmetric DOI | 10.1186/S12874-018-0509-7 |
P6409 | CORE ID | 160500318 |
P6179 | Dimensions Publication ID | 1105178437 |
P356 | DOI | 10.1186/S12874-018-0509-7 |
P953 | full work available at URL | http://eprints.whiterose.ac.uk/134842 |
P932 | PMC publication ID | 6022299 |
P698 | PubMed publication ID | 29954322 |
P1154 | Scopus EID | 2-s2.0-85049153640 |
P50 | author | Michael O'Dwyer | Q56447633 |
Susanne Schmitz | Q61846032 | ||
P2093 | author name string | James Morris | |
Ayesha Khan | |||
Jack Bowden | |||
Gordon Cook | |||
Cathal Walsh | |||
Isla Kuhn | |||
Kai Ruggeri | |||
Áine Maguire | |||
Vanessa Buchanan | |||
Elisa Haller | |||
Joy Leahy | |||
Natalia Homer | |||
P2860 | cites work | Current and emerging treatment options for patients with relapsed myeloma | Q26830878 |
Combination of direct and indirect evidence in mixed treatment comparisons | Q29619499 | ||
Incorporating data from various trial designs into a mixed treatment comparison model | Q30594247 | ||
Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension | Q30936117 | ||
Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma | Q33375404 | ||
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression | Q33376149 | ||
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 | ||
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). | Q33391803 | ||
Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide | Q33399196 | ||
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R | Q33401216 | ||
A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial | Q33408494 | ||
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes. | Q33409172 | ||
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | Q57904272 | ||
Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma | Q60997833 | ||
Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma | Q80332885 | ||
Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events | Q84519502 | ||
Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma | Q84587252 | ||
Multiple myeloma | Q86407303 | ||
Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients | Q89777946 | ||
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma | Q33409825 | ||
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial | Q33410172 | ||
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study | Q33410481 | ||
Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effective--a report by Polish Myeloma Study Group. | Q33415539 | ||
Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma | Q33416418 | ||
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Q33417762 | ||
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study | Q33428423 | ||
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma | Q33434817 | ||
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | Q33435789 | ||
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study | Q33942495 | ||
Mixed treatment comparisons using aggregate and individual participant level data | Q34327201 | ||
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 | ||
Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis | Q35104606 | ||
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial | Q35930659 | ||
Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. | Q36253136 | ||
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study | Q36382493 | ||
The treatment of relapsed and refractory multiple myeloma | Q37007400 | ||
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma | Q37219701 | ||
Treatment of multiple myeloma: a comprehensive review | Q37542173 | ||
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study | Q37655019 | ||
Emerging therapies for the treatment of relapsed or refractory multiple myeloma | Q37799862 | ||
Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. | Q38637962 | ||
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma | Q38939812 | ||
Systematic Review and Network Meta-Analysis of Treatment Outcomes for Multiple Myeloma | Q39430600 | ||
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group | Q39605645 | ||
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. | Q40392114 | ||
Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening | Q40734392 | ||
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | Q41700620 | ||
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program | Q43108154 | ||
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone | Q43195076 | ||
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research | Q43993739 | ||
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial | Q44735204 | ||
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio | Q46634193 | ||
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers | Q46902812 | ||
A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence | Q47626233 | ||
Endovascular Interventions for Femoropopliteal Peripheral Artery Disease: A Network Meta-Analysis of Current Technologies | Q47794965 | ||
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept | Q50129900 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P304 | page(s) | 66 | |
P577 | publication date | 2018-06-28 | |
P1433 | published in | BMC Medical Research Methodology | Q15752152 |
P1476 | title | The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. | |
P478 | volume | 18 |
Q64074928 | Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis | cites work | P2860 |
Search more.